Skip to main content
Top
Published in: Medical Oncology 7/2020

01-07-2020 | Metastasis | Original Paper

Immunohistochemical evaluation of microsatellite instability in resected colorectal liver metastases: a preliminary experience

Authors: Barabino Matteo, Piccolo Gaetano, Tosi Delfina, Masserano Riccardo, Santambrogio Roberto, Piozzi Guglielmo, Cigala Claudia, Luigiano Carmelo, Codecà Carla, Ferrari Daris, Ierardi Anna Maria, Bulfamante Gaetano, Gianpaolo Carrafiello, Opocher Enrico

Published in: Medical Oncology | Issue 7/2020

Login to get access

Abstract

In this retrospective study, we evaluated the predictive role of different immunohistochemical expression (IHC) of the mismatch repair proteins (MMR) in patients with colorectal liver metastasis (CRLM) submitted to liver resection. A total of 108 patients were retrieved, and 15 patients were excluded from the study because of the impossibility to obtain adequate formalin-fixed tissue blocks. The final analysis included 93 patients. Twenty-eight cases (30%) presented a no loss of expression or microsatellite stability (MSS) status, 59 cases (63%) showed a hybrid loss of expression, while 6 cases (7%) presented a complete loss of expression or microsatellite instability status (MSI). Patients with complete or hybrid loss of expression of MMR developed a high intra-hepatic recurrence rate compared to other ones (54% vs 21% OR of 4.278, 95% CI 1.53–11.93) (p = 0.004). The same difference in terms of liver recurrence has been found among patients with R0 resection (50% vs 17% OR of 0.2, 95% CI 0.06–0.65) (p = 0.005). However, there was no difference in terms of disease-free survival and overall survival. Complete or hybrid loss of expression of MMR could be considered a risk factor for intra-hepatic recurrences after liver resections for CRLM.
Literature
4.
go back to reference Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Teh C, Tejpar S, Van Cutsem E, Vauthey JN, Påhlman L. EGOSLIM (Expert Group on Onco Surgery management of Liver Metastases) group Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729–41. https://doi.org/10.1016/j.ctrv.2015.06.006.CrossRefPubMed Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Teh C, Tejpar S, Van Cutsem E, Vauthey JN, Påhlman L. EGOSLIM (Expert Group on Onco Surgery management of Liver Metastases) group Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729–41. https://​doi.​org/​10.​1016/​j.​ctrv.​2015.​06.​006.CrossRefPubMed
6.
go back to reference Adams RB, Haller DG, Roh MS. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1281–3.CrossRef Adams RB, Haller DG, Roh MS. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1281–3.CrossRef
8.
go back to reference Serrano PE, Gu CS, Husien M, Jalink D, Ritter A, Martel G, Tsang ME, Law CH, Hallet J, McAlister V, Sela N, Solomon H, Moulton CA, Gallinger S, Levine M. Risk factors for survival following recurrence after first liver resection for colorectal cancer liver metastases. J Surg Oncol. 2019. https://doi.org/10.1002/jso.25735.CrossRefPubMed Serrano PE, Gu CS, Husien M, Jalink D, Ritter A, Martel G, Tsang ME, Law CH, Hallet J, McAlister V, Sela N, Solomon H, Moulton CA, Gallinger S, Levine M. Risk factors for survival following recurrence after first liver resection for colorectal cancer liver metastases. J Surg Oncol. 2019. https://​doi.​org/​10.​1002/​jso.​25735.CrossRefPubMed
11.
go back to reference Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. https://doi.org/10.1200/JCO.2009.27.CrossRefPubMedPubMedCentral Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. https://​doi.​org/​10.​1200/​JCO.​2009.​27.CrossRefPubMedPubMedCentral
14.
go back to reference Zhang L, Peng Y, Peng G. Mismatch repair-based stratification for immune checkpoint blockade therapy. Am J Cancer Re. 2018;8(10):1977–88. Zhang L, Peng Y, Peng G. Mismatch repair-based stratification for immune checkpoint blockade therapy. Am J Cancer Re. 2018;8(10):1977–88.
15.
go back to reference National Comprehensive Cancer Network (NCCN) guidelines colon cancer, version 3.2019. National Comprehensive Cancer Network (NCCN) guidelines colon cancer, version 3.2019.
16.
17.
Metadata
Title
Immunohistochemical evaluation of microsatellite instability in resected colorectal liver metastases: a preliminary experience
Authors
Barabino Matteo
Piccolo Gaetano
Tosi Delfina
Masserano Riccardo
Santambrogio Roberto
Piozzi Guglielmo
Cigala Claudia
Luigiano Carmelo
Codecà Carla
Ferrari Daris
Ierardi Anna Maria
Bulfamante Gaetano
Gianpaolo Carrafiello
Opocher Enrico
Publication date
01-07-2020
Publisher
Springer US
Published in
Medical Oncology / Issue 7/2020
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-020-01388-4

Other articles of this Issue 7/2020

Medical Oncology 7/2020 Go to the issue